Project Summary/Abstract
Notch signaling both positively and negatively regulates differentiation and function of
osteoclasts, and signaling through the different Notch receptors is modulated through
glycosylation first by Protein O-fucosyltransferase 1 (POFUT1) and then by members of the
Fringe family of N-acetylglucosaminyl transferases. Multiple positions of the Notch extracellular
domain are subject to O-fucose extension by Fringes, and different Fringes (LFNG, MFGN, and
RFNG) demonstrate differences in both patterns of glycosylation and alteration in ligand-specific
receptor activation. Osteoclasts and their precursors express multiple Notch receptors and
ligands as well as all three Fringes, and this project will study the combinatorial effect of these
Fringes on activation of Notch receptors and resultant osteoclast formation and function. The
overall hypothesis for this study is combinations of Fringe-catalyzed glycosylation modulate
Notch signaling intensity and varying levels of Notch signaling produce either pro- or anti-
osteoclast effects. This will be tested in 2 specific aims. In aim 1, contributions of individual
Fringes will be investigated through targeted overexpression and knockdown followed by
quantification of Notch1 and Notch2 activation, osteoclast differentiation and activity, and
determination of Notch1 and Notch2 receptor glycosylation patterns. In aim 2, the relationship
between level of Notch signaling and osteoclast differentiation will be investigated through tuned
expression of active Notch1 and Notch2 intracellular domains in pre-osteoclasts followed by
high throughput RNA sequencing to determine patterns of Notch-regulated gene expression and
resultant level of osteoclast differentiation. Completion of this work will deepen understanding of
Notch modulation of osteoclast formation and function specifically, but also contribute to general
mechanisms of Notch signaling and the combinatorial effects of Fringe-mediated glycosylation.
In the long term, this knowledge may contribute to the development of new bone-preserving
therapies based on modulation, rather than total inhibition, of osteoclast activity.